CD4 and graft versus host disease: According to the results of the lymphocyte subset study, higher doses of PTCY (40 mg/kg or 29 mg/kg) presented a significantly lower CD4+ percentage, which was in accordance with previous report on the mechanism of PTCY inhibiting GvHD by limiting CD4+ subset proliferation in the early period of transplantation [30].